Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Booster doses of the original monovalent COVID-19 vaccine are associated with lower incidence of symptoms in health care personnel 6 weeks postinfection.

Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative ...

The global sales of attenuated vaccines are projected to soar, with an estimated worth of USD 5,068.2 million in 2024 and anticipated to reach USD 9,693.9 million by 2034. This growth trajectory ...

In a related JAMA Viewpoint, the authors noted that COVID-19 peaked in 2020 and 2021 as the third highest cause of mortality ...

The chair of the national vaccination committee on the latest vaccine developments and the importance for vulnerable groups ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

The monovalent XBB.1.5 COVID-19 vaccine is effective against XBB and JN lineage hospitalization; however, protection against the latter may be attenuated.

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

Premature infants of mothers who are HBsAg-positive All premature infants, regardless of weight, born to women who are HBsAg positive should receive HB immune globulin (HBIg) and monovalent HB vaccine ...